US4288627A
(en)
|
1980-02-12 |
1981-09-08 |
Phillips Petroleum Company |
Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
|
NZ202757A
(en)
|
1981-12-23 |
1985-11-08 |
Novo Industri As |
Peptides and medicaments
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DE69129226T2
(de)
|
1990-01-24 |
1998-07-30 |
Douglas I. Woodside Calif. Buckley |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
WO1991017243A1
(en)
|
1990-05-09 |
1991-11-14 |
Novo Nordisk A/S |
A cellulase preparation comprising an endoglucanase enzyme
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
WO1995005848A1
(en)
|
1993-08-24 |
1995-03-02 |
Novo Nordisk A/S |
Protracted glp-1
|
EP0717635B1
(en)
|
1993-09-07 |
2000-11-15 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5523449A
(en)
|
1995-05-17 |
1996-06-04 |
Bayer Corporation |
Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
|
ES2256888T3
(es)
|
1996-06-05 |
2006-07-16 |
Roche Diagnostics Gmbh |
Analogos de exendina, proceso para su preparacion y medicamentos que los contienen.
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
DE69739172D1
(de)
|
1996-08-08 |
2009-01-29 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
CA2468374C
(en)
|
1996-08-30 |
2010-12-21 |
Novo-Nordisk A/S |
Glp-1 derivatives
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
IL128828A0
(en)
|
1996-09-09 |
2000-01-31 |
Zealand Pharmaceuticals As |
Peptide prodrugs containing an alpha-hydroxy acid linker
|
CZ295838B6
(cs)
|
1996-09-09 |
2005-11-16 |
Zealand Pharma A/S |
Způsob výroby peptidů
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
AU5065198A
(en)
|
1996-11-15 |
1998-06-10 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
WO1998030231A1
(en)
|
1997-01-07 |
1998-07-16 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US6136784A
(en)
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
EP0981611A1
(en)
|
1997-02-05 |
2000-03-01 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
CA2289094A1
(en)
|
1997-05-07 |
1998-11-12 |
Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Berlin |
New cysteine derivatives, processes for their production, and pharmaceuticals containing them
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
NZ502592A
(en)
|
1997-08-08 |
2002-03-28 |
Amylin Pharmaceuticals Inc |
Exendin agonist peptides and their use in the treatment of type I and II diabetes
|
JP2001523688A
(ja)
|
1997-11-14 |
2001-11-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規エキセンジン・アゴニスト化合物
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
ES2294822T3
(es)
|
1997-11-14 |
2008-04-01 |
Amylin Pharmaceuticals, Inc. |
Compuestos novedosos de agonistas de exendina.
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
AU1617399A
(en)
|
1997-12-05 |
1999-06-28 |
Eli Lilly And Company |
Glp-1 formulations
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
CA2320371C
(en)
|
1998-02-13 |
2012-01-17 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
DE69942307D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
N-terminal veränderte glp-1 abkömmlinge
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するglp−1のglp−1誘導体及びエキセンジン
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
ATE269103T1
(de)
|
1998-03-13 |
2004-07-15 |
Novo Nordisk As |
Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
|
WO1999049788A1
(en)
|
1998-03-30 |
1999-10-07 |
Focus Surgery, Inc. |
Ablation system
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
EP1105460B1
(en)
|
1998-08-10 |
2009-10-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
|
JP2002526554A
(ja)
|
1998-10-07 |
2002-08-20 |
メディカル カレッジ オブ ジョージア リサーチ インスティチュート,インコーポレイテッド |
骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
CZ294029B6
(cs)
|
1998-12-07 |
2004-09-15 |
Societe De Conseils De Recherches Et D'application |
Analog GLP-1, jeho použití a farmaceutický prostředek jej obsahující
|
US6872700B1
(en)
|
1999-01-14 |
2005-03-29 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
PT1140145E
(pt)
|
1999-01-14 |
2005-11-30 |
Amylin Pharmaceuticals Inc |
Formulacoes novas de agonistas de exendina e metodos para a sua administracao
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
RU2001128068A
(ru)
|
1999-03-17 |
2004-02-20 |
Ново Нордиск А/С (DK) |
Способ ацилирования пептидов и новые ацилирующие агенты
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
ES2209885T3
(es)
|
1999-05-17 |
2004-07-01 |
Conjuchem, Inc. |
Peptidos insulinotropicos de larga duracion.
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
CA2395165C
(en)
|
2000-10-20 |
2012-05-22 |
Mario Ehlers |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
AU2002346491A1
(en)
|
2001-12-19 |
2003-07-09 |
Eli Lilly And Company |
Crystalline compositions for controlling blood glucose
|
KR20040070237A
(ko)
|
2001-12-20 |
2004-08-06 |
일라이 릴리 앤드 캄파니 |
연장된 작용 시간을 갖는 인슐린 분자
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
AU2004234345A1
(en)
|
2003-04-29 |
2004-11-11 |
Eli Lilly And Company |
Insulin analogs having protracted time action
|
EP1633390B1
(en)
*
|
2003-06-03 |
2012-01-18 |
Novo Nordisk A/S |
Stabilized pharmaceutical glp-1 peptide compositions
|
US7623530B2
(en)
|
2003-11-20 |
2009-11-24 |
Nokia Corporation |
Indication of service flow termination by network control to policy decision function
|
CA2554458A1
(en)
|
2004-01-30 |
2005-08-11 |
Waratah Pharmaceuticals, Inc. |
The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CA2586771A1
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
EP1883419A4
(en)
|
2005-05-06 |
2010-08-04 |
Bayer Pharmaceuticals Corp |
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
|
EP2351776A1
(en)
|
2005-06-13 |
2011-08-03 |
Imperial Innovations Limited |
Oxyntomodulin analogues and their effects on feeding behaviour
|
WO2007024899A2
(en)
|
2005-08-23 |
2007-03-01 |
The General Hospital Corporation |
Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
|
CN101534846B
(zh)
*
|
2005-11-07 |
2014-11-05 |
印第安纳大学研究及科技有限公司 |
显示生理学溶解性和稳定性的胰高血糖素类似物
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007095737A1
(en)
|
2006-02-21 |
2007-08-30 |
Waratah Pharmaceuticals Inc. |
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
|
AU2007221366B2
(en)
|
2006-02-22 |
2012-08-23 |
Msd Italia S.R.L. |
Oxyntomodulin derivatives
|
ME00581B
(me)
|
2006-07-18 |
2011-12-20 |
Sanofi Aventis |
Antagonisticna antitijela za tretman kancera polje pronalaska
|
ITMI20061607A1
(it)
|
2006-08-09 |
2008-02-10 |
Maria Vincenza Carriero |
Peptidi con attivita farmacologica
|
WO2008043033A2
(en)
|
2006-10-04 |
2008-04-10 |
Case Western Reserve University |
Fibrillation-resistant insulin and insulin analogues
|
MX2009004701A
(es)
|
2006-11-08 |
2009-05-21 |
Zealand Pharma As |
Analogos selectivos del peptido 2 similar al glucagon.
|
WO2008071010A1
(en)
|
2006-12-12 |
2008-06-19 |
Waratah Pharmaceuticals Inc. |
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
CN101578102B
(zh)
*
|
2007-01-05 |
2013-07-17 |
印第安纳大学研究及科技有限公司 |
在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
|
AU2008216265B2
(en)
|
2007-02-15 |
2014-04-03 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
DK2158214T3
(da)
|
2007-06-15 |
2011-12-05 |
Zealand Pharma As |
Glukagonanaloger
|
EP2025684A1
(en)
|
2007-08-15 |
2009-02-18 |
Zealand Pharma A/S |
Glucagon analogues
|
FR2917552B1
(fr)
|
2007-06-15 |
2009-08-28 |
Sagem Defense Securite |
Procede de regulation de la gigue de transmission au sein d'un terminal de reception
|
MX2010005317A
(es)
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
GB2455553B
(en)
|
2007-12-14 |
2012-10-24 |
Nuaire Ltd |
Motor mounting assembly for an axial fan
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DK2229407T3
(en)
|
2008-01-09 |
2017-02-27 |
Sanofi Aventis Deutschland |
NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
|
JP5695909B2
(ja)
|
2008-01-09 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
US8993516B2
(en)
|
2008-04-14 |
2015-03-31 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
RU2010147076A
(ru)
|
2008-04-22 |
2012-05-27 |
Кейз Вестерн Ризев Юнивесити (Us) |
Аналоги инсулина специфичные к изоформам
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
HUE028072T2
(en)
|
2008-06-17 |
2016-11-28 |
Univ Indiana Res & Tech Corp |
GIP-based agonists for the treatment of metabolic disease and obesity
|
ES2579502T3
(es)
|
2008-06-17 |
2016-08-11 |
Indiana University Research And Technology Corporation |
Coagonistas de receptores de glucagón/GLP-1
|
US8450270B2
(en)
*
|
2008-06-17 |
2013-05-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
PL219335B1
(pl)
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
AU2009276346B2
(en)
|
2008-07-31 |
2014-07-03 |
Case Western Reserve University |
Halogen-stabilized insulin
|
JP2011530508A
(ja)
|
2008-08-07 |
2011-12-22 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
|
WO2010029159A1
(en)
|
2008-09-12 |
2010-03-18 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
MX2011006314A
(es)
*
|
2008-12-15 |
2011-09-22 |
Zealand Pharma As |
Analogos de glucagon.
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
KR20110126591A
(ko)
*
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
CN102292348B
(zh)
|
2008-12-15 |
2015-07-08 |
西兰制药公司 |
胰高血糖素类似物
|
CA2747490C
(en)
|
2008-12-19 |
2017-02-14 |
Indiana University Research And Technology Corporation |
Insulin analogs
|
JP5755566B2
(ja)
|
2008-12-19 |
2015-07-29 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
アミド系インスリンプロドラッグ
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
US20100240883A1
(en)
|
2009-03-18 |
2010-09-23 |
Nian Wu |
Lipid-drug conjugates for drug delivery
|
CN101519446A
(zh)
|
2009-03-31 |
2009-09-02 |
上海一就生物医药有限公司 |
一种重组人胰岛素及其类似物的制备方法
|
SG175891A1
(en)
|
2009-05-08 |
2011-12-29 |
Genentech Inc |
Humanized anti-egfl7 antibodies and methods using same
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
DK2513140T3
(en)
|
2009-12-16 |
2016-01-18 |
Novo Nordisk As |
Double-acylated GLP-1 derivatives
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
MX342409B
(es)
|
2010-01-20 |
2016-09-28 |
Zealand Pharma As |
Tratamiento de enfermedades cardiacas.
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物
|
US20130143798A1
(en)
*
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
US20130053310A1
(en)
*
|
2010-03-26 |
2013-02-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
AU2011247824B2
(en)
|
2010-04-27 |
2014-02-13 |
Betta Pharmaceuticals Co., Ltd |
Glucagon-like peptide-1 analogue and use thereof
|
WO2011134471A1
(en)
|
2010-04-27 |
2011-11-03 |
Zealand Pharma A/S |
Peptide conjugates of glp-1 receptor agonists and gastrin and their use
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
SG186764A1
(en)
|
2010-06-24 |
2013-02-28 |
Zealand Pharma As |
Glucagon analogues
|
WO2011163473A1
(en)
*
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
US9708383B2
(en)
|
2010-11-09 |
2017-07-18 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
CA2824397A1
(en)
|
2011-01-20 |
2012-07-26 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
RU2013145013A
(ru)
|
2011-03-28 |
2015-05-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
CN103619175B
(zh)
|
2011-04-12 |
2016-08-17 |
诺沃—诺迪斯克有限公司 |
双酰化glp-1衍生物
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
EP2707713A2
(en)
|
2011-05-10 |
2014-03-19 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
US9453062B2
(en)
|
2011-06-10 |
2016-09-27 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
JP6352806B2
(ja)
|
2011-09-23 |
2018-07-04 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴン類似体
|
WO2013092703A2
(en)
|
2011-12-23 |
2013-06-27 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2013098408A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
CN104470948B
(zh)
|
2012-05-03 |
2018-06-15 |
西兰制药公司 |
Gip-glp-1双激动剂化合物及方法
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
JP6534927B2
(ja)
*
|
2012-07-23 |
2019-06-26 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
SG11201602965WA
(en)
|
2013-10-17 |
2016-05-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
RU2016134425A
(ru)
|
2014-02-18 |
2018-03-20 |
Ново Нордиск А/С |
Стабильные аналоги глюкагона и их применение для лечения гипогликемии
|
WO2016166289A1
(en)
|
2015-04-16 |
2016-10-20 |
Zealand Pharma A/S |
Acylated glucagon analogue
|